Jayasree Iyer – CEO, Access to Medicine Foundation
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Address: Oxfordlaan 70, 6229 EV Maastricht, Netherlands
Tel: + 31-43-35 09910
Web: http://www.pharmacell.nl/
PharmaCell provides contract services in the area of human cell & tissue banking & culturing as well as human cell line development and manufacturing of (bio) pharmaceuticals. Next to a GMP license, PharmaCell is the only commercial company in The Netherlands to hold an official license as Registered Tissue Establishment.
PharmaCell is also actively engaged in Research & Development work, both on behalf of some of its customers as well as in research consortia together with Universities, Academic Hospitals and other (bio)tech companies.
PharmaCell is located in the Biopartner Center Maastricht and, therefore, can take advantage of an extensive network to mediate in R&D, financing and housing requirements of clients. Close cooperation with Maastricht University and the associated Academic Hospital gives PharmaCell the unique capability to provide support and/or partnership to R&D companies to bring new products from the lab into the clinic.
PharmaCell offers fully integrated solutions for bio therapeutic proteins and (autologous and allogeneic) cell & tissue therapies, with established competencies which cover the full range of preclinical and clinical services for cell based biopharmaceuticals and therapies, including cell line development, cell banking, cell line characterization, process development and scale-up, custom cGMP manufacturing, lot release, stability testing and final product formulation and fill & finish. PharmaCell offers storage and distribution of Clinical Trail Materials including cell products and tissues and can also coordinate all logistics for autologous cell & tissue therapies throughout the European Union.
Our Maastricht facility was GMP certified in 2006 and in 2007 PharmaCell was granted an official licence as a Registered Tissue Establishment; the only company to hold such a license in The Netherlands.
PharmaCell operates a state-of-the art cGMP facility situated adjacent to the Maastricht University Hospital and within 15 minutes from both the German and Belgian border. Several airports are located close to Maastricht. The facility covers 250 square meters of clean room, classes A, B, C and D. (Classes 100 / 10,000 / 100,000), 180 square meters of R&D and QC laboratories including cryopreservation area.
All our customers have a single point of contact for the management of their project.
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
See our Cookie Privacy Policy Here